Outcomes of percutaneous coronary interventions in cancer patients

References

• Institute NNC. Cancer statistics 2018 [updated April 27, 2018; September 2, 2019]. Available from: https://www.cancer.gov/about-cancer/understanding/statistics
   Google Scholar
• Sciences NDoCCP. Statistics 2019 [updated Feb 8, 2019;September 2, 2019]. Available from: https://cancercontrol.cancer.gov/ocs/statistics/statistics.html
   Google Scholar
• Koene RJ, Prizment AE, Blaes A, et al. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016 Mar 15;133(11):1104–1114.
   PubMed Web of Science ®Google Scholar
• Potts JE, Iliescu CA, Lopez Mattei JC, et al. Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States. Eur Heart J. 2019 Jun 7;40(22):1790–1800.
   PubMed Web of Science ®Google Scholar
• Landes U, Kornowski R, Bental T, et al. Long-term outcomes after percutaneous coronary interventions in cancer survivors. Coron Artery Dis. 2017 Jan;28(1):5–10.
   PubMed Web of Science ®Google Scholar
• Borovac JA, Kwok CS, Iliescu C, et al. Percutaneous coronary intervention and outcomes in patients with lymphoma in the United States (Nationwide Inpatient Sample [NIS] Analysis). Am J Cardiol. 2019 Jul;124(8):1190–1197.
   Google Scholar
• Potts J, Mohamed MO, Lopez Mattei JC, et al. Percutaneous coronary intervention and in-hospital outcomes in patients with leukemia: a nationwide analysis. Catheter Cardiovasc Interv. 2019 Aug;13:1–11.
   Google Scholar
• Pothineni NV, Shah NN, Rochlani Y, et al. Temporal trends and outcomes of acute myocardial infarction in patients with cancer. Ann Transl Med. 2017 Dec;5(24):482.
   PubMed Web of Science ®Google Scholar
• Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002 Mar 5;105(9):1135–1143.
   PubMed Web of Science ®Google Scholar
• Scalone G, Niccoli G, Refaat H, et al. Not all plaque ruptures are born equal: an optical coherence tomography study. Eur Heart J Cardiovasc Imaging. 2017 Nov 1;18(11):1271–1277.
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010 Mar 19;140(6):883–899.
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001 Feb 17;357(9255):539–545.
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002 Dec 19–26;420(6917):860–867.
   PubMed Web of Science ®Google Scholar
• Nelson ER, Wardell SE, Jasper JS, et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science. 2013 Nov 29;342(6162):1094–1098.
   PubMed Web of Science ®Google Scholar
• Kamp DW, Shacter E, Weitzman SA. Chronic inflammation and cancer: the role of the mitochondria. Oncology (Williston Park). 2011 Apr 30;25(5):400–10, 413.
   PubMed Web of Science ®Google Scholar
• Libby P, Ebert BLCHIP. Clonal hematopoiesis of indeterminate potential. Circulation. 2018 Aug 14;138(7):666–668.
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017 Jul 13;377(2):111–121.
   PubMed Web of Science ®Google Scholar
• Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009 Jun 16;53(24):2231–2247.
   PubMed Web of Science ®Google Scholar
• Lee MS, Finch W, Mahmud E. Cardiovascular complications of radiotherapy. Am J Cardiol. 2013 Nov 15;112(10):1688–1696.
   PubMed Web of Science ®Google Scholar
• Floyd JD, Nguyen DT, Lobins RL, et al. Cardiotoxicity of cancer therapy. J Clin Oncol. 2005 Oct 20;23(30):7685–7696.
   PubMed Web of Science ®Google Scholar
• Arunprasath P, Gobu P, Dubashi B, et al. Rituximab induced myocardial infarction: A fatal drug reaction. J Cancer Res Ther. 2011 Jul-Sep;7(3):346–348.
   PubMed Web of Science ®Google Scholar
• Economopoulou P, Kotsakis A, Kapiris I, et al. Cancer therapy and cardiovascular risk: focus on bevacizumab. Cancer Manag Res. 2015;7:133–143.
   PubMed Web of Science ®Google Scholar
• Amir E, Seruga B, Niraula S, et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011 Sep 7;103(17):1299–1309.
   PubMed Web of Science ®Google Scholar
• Nanda A, Chen MH, Braccioforte MH, et al. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA. 2009 Aug 26;302(8):866–873.
   PubMed Web of Science ®Google Scholar
• Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016 Sep 21;37(36):2768–2801.
   PubMed Web of Science ®Google Scholar
• Hess CN, Roe MT, Clare RM, et al. Relationship between cancer and cardiovascular outcomes following percutaneous coronary intervention. J Am Heart Assoc. 2015 Jul 6;4(7):e001779.
   PubMed Web of Science ®Google Scholar
• Iannaccone M, D’Ascenzo F, Vadala P, et al. Prevalence and outcome of patients with cancer and acute coronary syndrome undergoing percutaneous coronary intervention: a BleeMACS substudy. Eur Heart J Acute Cardiovasc Care. 2018 Oct;7(7):631–638.
   PubMed Web of Science ®Google Scholar
• Blann AD, Dunmore S. Arterial and venous thrombosis in cancer patients. Cardiol Res Pract. 2011 3;Mar(2011):394740.
   Google Scholar
• Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation. 2019 Jul 16;140(3):240–261.
   PubMed Web of Science ®Google Scholar
• Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation. 2011 Jun 14;123(23):2736–2747.
   PubMed Web of Science ®Google Scholar
• Castaman G, Pieri L. Management of thrombocytopenia in cancer. Thromb Res. 2018 Apr;164(Suppl 1):S89–S93.
   PubMedGoogle Scholar
• Elting LS, Rubenstein EB, Martin CG, et al. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol. 2001 Feb 15;19(4):1137–1146.
   PubMed Web of Science ®Google Scholar
• Hakim DA, Dangas GD, Caixeta A, et al. Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: analysis from the harmonizing outcomes with revascularization and stents in acute myocardial infarction (HORIZONS-AMI) trial. Am Heart J. 2011 Feb;161(2):391–396.
   PubMed Web of Science ®Google Scholar
• Ayoub K, Marji M, Ogunbayo G, et al. Impact of chronic thrombocytopenia on in-hospital outcomes after percutaneous coronary intervention. JACC Cardiovasc Interv. 2018 Sep 24;11(18):1862–1868.
   PubMed Web of Science ®Google Scholar
• Kwok CS, Tiong D, Pradhan A, et al. Meta-analysis of the prognostic impact of anemia in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2016 Aug 15;118(4):610–620.
   PubMed Web of Science ®Google Scholar
• Pilgrim T, Vetterli F, Kalesan B, et al. The impact of anemia on long-term clinical outcome in patients undergoing revascularization with the unrestricted use of drug-eluting stents. Circ Cardiovasc Interv. 2012 Apr;5(2):202–210.
   PubMed Web of Science ®Google Scholar
• Giza DE, Marmagkiolis K, Mouhayar E, et al. Management of CAD in patients with active cancer: the interventional cardiologists’ perspective. Curr Cardiol Rep. 2017 Jun;19(6):56.
   PubMed Web of Science ®Google Scholar
• Tabata N, Sueta D, Yamamoto E, et al. Outcome of current and history of cancer on the risk of cardiovascular events following percutaneous coronary intervention: a Kumamoto University Malignancy and Atherosclerosis (KUMA) study. Eur Heart J Qual Care Clin Outcomes. 2018 Oct 1;4(4):290–300.
   PubMed Web of Science ®Google Scholar
• Velders MA, Boden H, Hofma SH, et al. Outcome after ST elevation myocardial infarction in patients with cancer treated with primary percutaneous coronary intervention. Am J Cardiol. 2013 Dec 15;112(12):1867–1872.
   PubMed Web of Science ®Google Scholar
• Quintana RA, Monlezun DJ, Davogustto G, et al. Outcomes following percutaneous coronary intervention in patients with cancer. Int J Cardiol. 2019 Sep 12;300:106–112.
   PubMedGoogle Scholar
• Tabata N, Sueta D, Yamamoto E, et al. A retrospective study of arterial stiffness and subsequent clinical outcomes in cancer patients undergoing percutaneous coronary intervention. J Hypertens. 2019 Apr;37(4):754–764.
   PubMed Web of Science ®Google Scholar
• Shivaraju A, Patel V, Fonarow GC, et al. Temporal trends in gastrointestinal bleeding associated with percutaneous coronary intervention: analysis of the 1998-2006 Nationwide Inpatient Sample (NIS) database. Am Heart J. 2011 Dec;162(6):1062–1068 e5.
   PubMed Web of Science ®Google Scholar
• van Werkum JW, Heestermans AA, Zomer AC, et al. Predictors of coronary stent thrombosis: the Dutch stent thrombosis registry. J Am Coll Cardiol. 2009 Apr 21;53(16):1399–1409.
   PubMed Web of Science ®Google Scholar
• Wang F, Gulati R, Lennon RJ, et al. Cancer history portends worse acute and long-term noncardiac (but Not Cardiac) mortality after primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Mayo Clin Proc. 2016 Dec;91(12):1680–1692.
   PubMed Web of Science ®Google Scholar
• Patel MR, Dehmer GJ, Hirshfeld JW, et al. ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 Appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol. 2012 Feb 28;59(9):857–881.
   PubMedGoogle Scholar
• Iliescu C, Grines CL, Herrmann J, et al. SCAI expert consensus statement: evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (Endorsed by the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencionista). Catheter Cardiovasc Interv. 2016 Apr;87(5):895–899.
   PubMedGoogle Scholar
• Ferrante G, Rao SV, Juni P, et al. Radial versus femoral access for coronary interventions across the entire spectrum of patients with coronary artery disease: a meta-analysis of randomized trials. JACC Cardiovasc Interv. 2016 Jul 25;9(14):1419–1434.
   PubMed Web of Science ®Google Scholar
• Yadav PK, Bagur R, Baquero GA, et al. Safety and feasibility of transradial catheterization in breast cancer survivors: A 2-center international experience. JACC Cardiovasc Interv. 2015 Apr 20;8(4):639–641.
   PubMed Web of Science ®Google Scholar
• Iliescu C, Durand JB, Kroll M. Cardiovascular interventions in thrombocytopenic cancer patients. Tex Heart Inst J. 2011;38(3):259–260.
   PubMed Web of Science ®Google Scholar
• Iliescu C, Balanescu DV, Donisan T, et al. Safety of diagnostic and therapeutic cardiac catheterization in cancer patients with acute coronary syndrome and chronic thrombocytopenia. Am J Cardiol. 2018 Nov 1;122(9):1465–1470.
   PubMed Web of Science ®Google Scholar
• Iliescu CA, Cilingiroglu M, Giza DE, et al. Bringing on the light” in a complex clinical scenario: optical coherence tomography-guided discontinuation of antiplatelet therapy in cancer patients with coronary artery disease (PROTECT-OCT registry). Am Heart J. 2017;194:83–91.
   PubMed Web of Science ®Google Scholar
• Urban P, Meredith IT, Abizaid A, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015 Nov 19;373(21):2038–2047.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Patialiakas A, Thury A, et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol. 2015 Mar 3;65(8):805–815.
   PubMed Web of Science ®Google Scholar
• Campia U, Moslehi JJ, Amiri-Kordestani L, et al. Cardio-oncology: vascular and metabolic perspectives: a scientific statement from the American Heart Association. Circulation. 2019 Mar 26;139(13):e579–e602.
   PubMed Web of Science ®Google Scholar
• Hayden AJ, Rains M, Tiver K. Deep inspiration breath hold technique reduces heart dose from radiotherapy for left-sided breast cancer. J Med Imaging Radiat Oncol. 2012 Aug;56(4):464–472.
   PubMed Web of Science ®Google Scholar
• Welsh B, Chao M, Foroudi F. Reducing cardiac doses: a novel multi-leaf collimator modification technique to reduce left anterior descending coronary artery dose in patients with left-sided breast cancer. J Med Radiat Sci. 2017 Jun;64(2):114–119.
   PubMed Web of Science ®Google Scholar
• Singh M. Bleeding avoidance strategies during percutaneous coronary interventions. J Am Coll Cardiol. 2015 May 26;65(20):2225–2238.
   PubMed Web of Science ®Google Scholar
• Jolly SS, Yusuf S, Cairns J, et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet. 2011 Apr 23;377(9775):1409–1420.
   PubMed Web of Science ®Google Scholar
• Mason PJ, Shah B, JE T-H, et al. An update on radial artery access and best practices for transradial coronary angiography and intervention in acute coronary syndrome: a scientific statement from the American Heart Association. Circ Cardiovasc Interv. 2018 Sep;11(9):e000035.
   PubMed Web of Science ®Google Scholar
• Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019 Sep 26;381:2032–2042.
   Web of Science ®Google Scholar
• Watanabe H, Domei T, Morimoto T, et al. Very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk: insight from the STOPDAPT-2 trial. Circulation. 2019 Sep 27;140:1957–1959.
   Web of Science ®Google Scholar
• Hahn JY, Song YB, Oh JH, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. JAMA. 2019 Jun 25;321(24):2428–2437.
   PubMed Web of Science ®Google Scholar